Recent Posts

$8M Fosamax Verdict Remitted By MDL Judge To $1.5M Or New Damages Trial
Posted on 5 Oct 2010 by Tom Moylan

NEW YORK -- (Mealey's) The New York federal judge overseeing the Fosamax multidistrict litigation on Oct. 4 sua sponte found that an $8 million verdict in a bellwether trial is excessive and ordered a remittitur of the verdict to $1.5 million unless... Read More

Fosamax MDL Jury: Drug Wasn't Defectively Designed, Didn't Cause Jaw Injury
Posted on 3 Oct 2011 by Tom Moylan

NEW YORK - A New York federal jury hearing the fourth Fosamax bellwether trial on Oct. 3 found that Merck's osteoporosis drug was not defectively designed and did not cause a plaintiff to develop osteonecrosis of the jaw (ONJ) ( In Re: Fosamax Products... Read More

Merck Wins Defense Verdict In 1st Fosamax Femur Case To Go To Verdict
Posted on 1 May 2013 by Tom Moylan

TRENTON, N.J. - (Mealey's) A New Jersey federal jury on April 29 quickly found that Fosamax did not cause a plaintiff's femur fracture, the first verdict in a case in which a plaintiff claims that the osteoporosis drug weakened her thigh bone... Read More

Jury Finds For Merck In Bellwether Fosamax Jaw Disease Trial
Posted on 22 Nov 2010 by Tom Moylan

NEW YORK - (Mealey's) A federal court jury in New York on Nov. 19 found that Merck & Co. Inc.'s osteoporosis drug Fosamax did not cause the osteonecrosis that destroyed a Florida woman's jaw ( Judith Graves v. Merck & Co. Inc. , 1... Read More

Merck To Settle Suits Alleging Jaw Damage From Osteoporosis Drug
Posted on 10 Dec 2013 by Michael Lefkowitz

WHITEHOUSE STATION, N.J. — (Mealey's) Merck & Co. Inc. has agreed to pay $27.7 million to resolve product liability suits alleging that its osteoporosis drug Fosamax caused osteonecrosis of the jaw (ONJ), or bone death, according to a press... Read More

Eli Lilly Loses Patent Lawsuit For Drug Strattera
Posted on 13 Aug 2010 by LexisNexis Litigation Resource Community Staff

INDIANAPOLIS - (AP) Eli Lilly & Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention deficit hyperactivity drug Strattera. The U.S. District Court for the District of New Jersey ruled against the... Read More